VF
UBX

Virtu Financial’s Unity Biotechnology UBX Stock Holding History

Virtu Financial’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,046
Closed -$19K – 2043
2025
Q1 		$19K Buy
+18,046
New +$32.6K ﹤0.01% 1112
2023
Q3 		– Sell
-17,949
Closed -$46K – 1923
2023
Q2 		$46K Buy
+17,949
New +$47.4K ﹤0.01% 1150
2023
Q1 		– Sell
-20,155
Closed -$55K – 2119
2022
Q4 		$55K Buy
20,155
+16,645
+474% +$48.4K 0.01% 1064
2022
Q3 		$14K Sell
3,510
-2,754
-44% -$17.4K ﹤0.01% 1476
2022
Q2 		$35K Buy
6,264
+1,268
+25% +$10.6K ﹤0.01% 1216
2022
Q1 		$56K Sell
4,996
-335
-6% -$3.76K ﹤0.01% 1103
2021
Q4 		$78K Buy
+5,331
New +$117K 0.01% 1225
2020
Q4 		– Sell
-5,172
Closed -$179K – 1810
2020
Q3 		$179K Buy
+5,172
New +$328K 0.03% 608

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial's UBX Position: Q2 2025 in Review

Virtu Financial sold out of Unity Biotechnology (UBX) in Q2 2025, closing a stake of 18,046 shares — an estimated $19K sold.

Virtu Financial first reported a position in UBX in Q3 2020 and held it in 8 quarters. The position peaked at $179K in Q3 2020. 35 funds tracked by Wall St. Rank hold UBX as of Q2 2025.

  • Virtu Financial reported no remaining Unity Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Virtu Financial sold 18,046 Unity Biotechnology shares in Q2 2025, an estimated $19K.
  • Virtu Financial first reported a position in Unity Biotechnology in Q3 2020 and held it in 8 quarters.
  • Virtu Financial's Unity Biotechnology position peaked at $179K in Q3 2020.
  • 35 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2025.

Based on Virtu Financial's 13F filing for Q2 2025, filed 12 Aug 2025.